Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, Skype calls, and the like has, of course, predictably returned. To cope, we are brewing the usual number of cups of stimulation — actually, we have lost count — as we dig in for another busy day. On that note, here are a few tidbits to get you going. We hope your day goes well and, as always, please do keep in touch.

A new coalition of Fortune 500 companies called EmployersRx is hoping to push lawmakers to start thinking about drug pricing policies that will affect the broadest number of Americans, not just changes to federal programs, STAT writes. Called EmployerRx, the group has not formally endorsed the House Democratic bill that would give Medicare a chance to buy drugs at negotiated prices, but its coy position is a startling departure from the rest of the business community, which has blasted the bill as socialist and bad for business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy